Medefil, Inc.
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- United States
- Registered address
- 250 Windy Point Drive, Glendale Heights, Illinois (IL) 60139, United States (USA)
- Operations here
- analysislabelmanufacturepackrelabelrepacksterilize
- FDA identifiers
- FEI 3001677091 · DUNS 016448669
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- VAIDrug Quality Assurance2025-04-21
- VAIDrug Quality Assurance2018-03-29
- VAIDrug Quality Assurance2016-06-17
- VAIDrug Quality Assurance2014-09-15
- VAIDrug Quality Assurance2012-12-20
- NAIBioresearch Monitoring2012-08-22
- VAIDrug Quality Assurance2012-05-25
- OAIDrug Quality Assurance2011-09-06
- NAIDrug Quality Assurance2010-02-11
Drugs this plant is listed as making
3 distinct drugs across 3 products name this site in their FDA label.
- Atropine Sulfate Injectionin shortageMedefil, Inc.
- Calcium Chloride InjectionMedefil, Inc.
- Sterile Water for Injectionin shortageMedefil, Inc.
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.